Open Source Securities released a research report on April 18 stating that it gave Kaishi Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) R&D innovation enriches the product pipeline, and two-wheel drive in the soft mirror+ultrasound business unlocks greater performance potential; 2) the revenue scale effect has been formed, and the net profit growth rate is expected to exceed the revenue growth rate. (Mainichi Keizai Shimbun)
开源证券4月18日发布研报称，给予开立医疗（300633.SZ）买入评级。评级理由主要包括：1）研发创新丰富产品管线，软镜+超声业务双轮驱动释放更大业绩潜力；2）营收规模效应已经形成，净利润增速有望超越营收增速。（每日经济新闻）
Open Source Securities released a research report on April 18 stating that it gave Kaishi Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) R&D innovation enriches the product pipeline, and two-wheel drive in the soft m
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.